| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | dorzolamide (Eydelto®) |
| Formulation | 20 mg/ml eye drops |
| Reference number | 3560 |
| Indication | As adjunctive therapy to beta-blockers, as monotherapy in patients unresponsive to beta-blockers or in whom beta- blockers are contraindicated, in the treatment of elevated intra-ocular pressure in: ocular hypertension, open-angle glaucoma, pseudoexfoliative glaucoma |
| Company | Aspire Pharma Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 27/07/2017 |